Professor, Medicine, Vanderbilt University School of Medicine
Pulmonology
Dr. Pierre Massion, MD
|
|
Give Review
Pierre Massion works in the field of Pulmonology. Pierre Massion is also published. He has 59 publications published. The lastest publication: "Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?' He is registered with Medicare and accepts Medicare payments.
Publications
- Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
- Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung.
- Validation of a multiprotein plasma classifier to identify benign lung nodules.
- The RNA binding protein FXR1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers.
- Targeting SLC1A5-mediated glutamine dependence in non-small cell lung cancer.
- Indeterminate pulmonary nodules: risk for having or for developing lung cancer?
- Extensive Phenotyping of Individuals At-risk for Familial Interstitial Pneumonia Reveals Clues to the Pathogenesis of Interstitial Lung Disease.
- Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.
- Predicting Lung Cancer Prior to Surgical Resection in Patients with Lung Nodules.
- Acyl-coenzyme a-binding protein regulates Beta-oxidation required for growth and survival of non-small cell lung cancer.
- Toward Rapid, High-Sensitivity, Volume-Constrained Biomarker Quantification and Validation using Backscattering Interferometry.
- Discovery of new membrane-associated proteins overexpressed in small-cell lung cancer.
- A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.
- Integrative Genomics Analysis Identifies Candidate Drivers at 3q26-29 Amplicon in Squamous Cell Carcinoma of the Lung.
- ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma.
- Poor survival for veterans with pathologic stage I non-small-cell lung cancer.
- The state of molecular biomarkers for the early detection of lung cancer.
- Loss of polymeric immunoglobulin receptor expression is associated with lung tumourigenesis.
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers.
- Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.
- Thoracic Operations for Pulmonary Nodules Are Frequently Not Futile in Patients with Benign Disease.
- Bronchial Secretory IgA Deficiency Correlates With Airway Inflammation and Progression of COPD.
- Expression of focal adhesion kinase in small-cell lung carcinoma.
- Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry.
- Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq.
- Oral iloprost improves endobronchial dysplasia in former smokers.
- Role of STRAP in regulating GSK3β function and Notch3 stabilization.
- Advances in proteomic strategies toward the early detection of lung cancer.
- Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions.
- Evolving concepts in lung carcinogenesis.
- A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.
- Preferential localization of human origins of DNA replication at the 5'-ends of expressed genes and at evolutionarily conserved DNA sequences.
- National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection...
- Airway PI3K pathway activation is an early and reversible event in lung cancer development.
- Mass spectrometry-based proteomic profiling of lung cancer.
- Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer.
- Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
- IkappaB kinase-alpha regulates endothelial cell motility and tumor angiogenesis.
- Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer.
- Smoking-related genomic signatures in non-small cell lung cancer.
- Role of chromosome 3q amplification in lung cancer.
- Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.
- Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer.
- Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors...
- PDGFR-beta expression in small cell lung cancer patients.
- Proteomic strategies for the characterization and the early detection of lung cancer.
- PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
- Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
- Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas.
- Proteomic patterns of preinvasive bronchial lesions.
- Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression.
- 15-Lipoxygenase-2 expression in benign and neoplastic lung: an immunohistochemical study and correlation with tumor grade and proliferation.
- Role of p63 amplification and overexpression in lung cancer development.
- Significance of p63 amplification and overexpression in lung cancer development and prognosis.
- From clinical and pathologic to molecular staging of lung cancer.
- Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
- Chronic Obstructive Pulmonary Disease and Subsequent Overall and Lung Cancer Mortality in Low-Income Adults.
- Early Detection of NSCLC with scFv Selected against IgM Autoantibody.
Procedures Preformed
- Bronchoscopy
- Thoracentesis
Doctors Specialties
- Pulmonary Critical Care Medicine
- Pulmonology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Network S
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- GEHA
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- Meritain Health
- PHCS Network PPO
- Mutual of Omaha
- POMCO Group
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
UCSF -
Catholic University of Leuven
Hospital
-
Vanderbilt Hospital and Clinics
Drug Facts
| NPI NUMBER | 1629152723 | |
| NPPES Provider LastName | MASSION | |
| NPPES Provider FirstName | PIERRE | |
| NPPES Provider ZIPCode | 37212 | |
| NPPES Provider State | TN | |
| Specialty Description | Pulmonary Disease | |
| Total Claim Count | 29.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629152723 |
| Last Name Of The Provider | MASSION |
| First Name Of The Provider | PIERRE |
| View All |
Similar Doctors
|
Dr. Otis B. Rickman, DO
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Benjamin A. Ferrell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Trochtenberg, MD |
|
|
Dr. Tina Hartert, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Arthur Wheeler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lorraine Ware, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Toby R. Smith, MD
This Doctor is OpenDoctor Recommended.
|